Clinical Trial Update: Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients [Phase 2]

View source ↗

Summary

Amgen reports results from a Phase 2 trial of MP-376 in cystic fibrosis patients over 28 days, assessing safety, tolerability, and efficacy. The update summariz…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• MP-376

Snippet

Sponsor: Amgen | Conditions: Cystic Fibrosis (CF) | Phase 2 | Status: COMPLETED | Results posted: 2012-06-12